Dabogratinib (GMP)
Dabogratinib (GMP) is Dabogratinib produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib (GMP) is an orally active, selective inhibitor for FGFR3 with an IC50 of 11 nM. Dabogratinib (GMP) exhibits antitumor efficacy against urothelial cancers and solid tumors[1].
Product Specifications
CAS Number
2800223-30-5
UNSPSC
12352005
Target
FGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tyra-300-gmp.html
Smiles
O=S(N(C1)CC1(C2)CN2C(N=C3)=CC=C3C4=NNC5=CC=C(O[C@H](C)C6=C(Cl)C=NC=C6Cl)C=C54)(C)=O
Molecular Formula
C25H24Cl2N6O3S
Molecular Weight
559.47
References & Citations
[1]Hudkins RL, et al., Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia. J Med Chem. 2024 Sep 26;67 (18) :16737-16756.
Shipping Conditions
Room temperature
Scientific Category
GMP Small Molecules
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC801037-500 1x 500 µL
CD44 Standard (DF1485), CF680 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470040-500 1x 500 µL
CD35 / CR1 (E11), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740031-500 1x 500 µL
Mucin 5AC (MUC5AC) (45M1), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470096-100 1x 100 µL
Histone H1 (AE-4), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 